IMP-3 is a novel progression marker in malignant melanoma

Modern Pathology

Volumn 21, Issue 4, 2008, Pages 431-437

  Pryor, Jennifer G ^a   Bourne, Patricia A ^a   Yang, Qi ^a   Spaulding, Betsy O ^b   Scott, Glynis A ^a   Xu, Haodong ^a,c  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b AGILENT TECHNOLOGIES   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Diagnostic marker; IMP 3; KOC; Melanoma; Progression marker; Spitz nevus

Indexed keywords

PROTEIN IMP 3; SOMATOMEDIN B; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DYSPLASTIC NEVUS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; MALE; MELANOMA; METASTASIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEVUS; PRECANCEROUS CONDITIONS; RNA-BINDING PROTEINS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 41149096677     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3801016     Document Type: Article

References (23)

1. Bron JL, Jaspars EH, Molenkamp BG, et al. Three patients with a Spitz naevus that later turned out to be a melanoma. Ned Tijdschr Geneeskd 2005;149:1852-1858.
2. Troxel D. Medicolegal aspects of error in pathology. Arch Pathol Lab Med 2006;130:617-619.
3. Bergman R, Malkin L, Sabo E, et al. MIB-1 monoclonal antibody to determine proliferative activity of Ki-67 antigen as an adjunct to the histopathologic differential diagnosis of Spitz nevi. J Am Acad Dermatol 2001;44:500-504.
4. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007;17:117-127.
5. Clark Jr WH, Elder DE, Guerry DIV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;81:1893-1904.
6. Guerry D, Synnestvedt M, Elder DE, et al. Lessons from tumor progression: the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993;100:342S-345S.
7. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. Braz J Med Biol Res 2003;36:347-350.
8. Bedrosian I, Faries MB, Guerry DT, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or =1mm) with vertical growth phase. Ann Surg Oncol 2000;7:262-267.
9. Cecchi R, Buralli L, Innocenti S, et al. Sentinel lymph node biopsy in patients with thin melanomas. J Dermatol 2007;34:512-515.
10. Morton DL, Thompson JF, Cochran AJ, et al. Sentinelnode biopsy or nodal observation in melanoma. N Engl J Med 2006;355:1307-1317.
11. Ramsden AJ, Grover R, Chana J, et al. A prospective analysis of c-myc oncoprotein levels as a prognostic marker in malignant melanoma. J Plast Reconstr Aesthet Surg 2007;60:626-630.
12. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25:1129-1134.
13. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol 1999;19:1262-1270.
14. Müeller-Pillasch UL, Wallrapp C, Micha A, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997;14:2729-2733.
15. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells. J Biol Chem 2005;280:18517-18524.
16. Hammer NA, Hansen TvO, Byskov AG, et al. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 2005;130:203-212.
17. Simon R, Bourne PA, Yang Q, et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Hum Pathol 2007;38:1178-1183.
18. Gu L, Shigemasa K, Ohama K. Increased expression of IGF II mRNA-binding protein 1 mRNA is associated with an advanced clinical stage and poor prognosis in patients with ovarian cancer. Int J Oncol 2004;24:671-678.
19. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 2005;29:188-195.
20. Xu H, Bourne PA, Spaulding BO, et al. High-grade neuroendocrine carcinomas of the lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 2007;38:555-563.
21. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 2003;88:887-894.
22. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006;7:556-564.
23. Greene F, Page D, Fleming I, Fritz A, Balch C, Haller D, Morrow M (eds). AJCC Cancer Staging Manual, 6th edn. Springer-Verlag: Berlin/Heidelberg/New York/London/Paris/Tokyo/Hong Kong, 2002. 435pp.